Insider Selling: Alpha Tau Medical (NASDAQ:DRTS) CFO Sells $220,000.00 in Stock

Alpha Tau Medical Ltd. (NASDAQ:DRTS) CFO Raphi Levy sold 20,000 shares of Alpha Tau Medical stock in a transaction on Thursday, June 25th. The shares were sold at an average price of $11.00, for a total value of $220,000.00. Following the completion of the sale, the chief financial officer directly owned 110,180 shares of the company’s stock, valued at approximately $1,211,980. This represents a 15.36% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Raphi Levy also recently made the following trade(s):

• On Tuesday, June 23rd, Raphi Levy sold 17,500 shares of Alpha Tau Medical stock. The stock was sold at an average price of $9.55, for a total transaction of $167,125.00.
• On Wednesday, June 3rd, Raphi Levy sold 32,500 shares of Alpha Tau Medical stock. The stock was sold at an average price of $10.83, for a total value of $351,975.00.

Alpha Tau Medical Stock Performance

NASDAQ DRTS opened at $10.88 on Monday. The firm has a market capitalization of $982.79 million, a P/E ratio of -16.24 and a beta of 1.19. Alpha Tau Medical Ltd. has a 1-year low of $2.87 and a 1-year high of $11.62. The company has a debt-to-equity ratio of 0.09, a current ratio of 7.79 and a quick ratio of 7.79. The business’s 50-day simple moving average is $9.39 and its 200-day simple moving average is $7.64.

Alpha Tau Medical (NASDAQ:DRTS) last announced its quarterly earnings results on Monday, May 18th. The company reported ($0.26) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.13). Equities analysts predict that Alpha Tau Medical Ltd. will post -0.67 EPS for the current year.

Institutional Trading of Alpha Tau Medical

Hedge funds have recently added to or reduced their stakes in the business. Envestnet Asset Management Inc. bought a new stake in shares of Alpha Tau Medical during the 3rd quarter worth about $62,000. Bank of America Corp DE boosted its holdings in shares of Alpha Tau Medical by 2,779.1% in the third quarter. Bank of America Corp DE now owns 22,457 shares of the company’s stock valued at $101,000 after acquiring an additional 21,677 shares in the last quarter. Millennium Management LLC acquired a new position in shares of Alpha Tau Medical during the third quarter valued at approximately $170,000. Mariner LLC increased its stake in shares of Alpha Tau Medical by 185.8% during the third quarter. Mariner LLC now owns 123,250 shares of the company’s stock valued at $556,000 after acquiring an additional 80,129 shares during the period. Finally, Apella Capital LLC bought a new stake in Alpha Tau Medical during the fourth quarter worth approximately $1,892,000. Institutional investors own 2.65% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on DRTS. Barclays boosted their price target on Alpha Tau Medical from $15.00 to $17.00 and gave the company an “overweight” rating in a report on Thursday, June 4th. HC Wainwright reiterated a “buy” rating and set a $15.00 target price on shares of Alpha Tau Medical in a research note on Tuesday, June 2nd. LADENBURG THALM/SH SH raised their price target on shares of Alpha Tau Medical from $12.00 to $14.00 and gave the stock a “buy” rating in a research report on Tuesday, May 12th. Piper Sandler lifted their price target on shares of Alpha Tau Medical from $5.00 to $8.00 and gave the company a “neutral” rating in a report on Tuesday, May 19th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Alpha Tau Medical in a research report on Monday, April 20th. Four research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Alpha Tau Medical presently has a consensus rating of “Hold” and a consensus target price of $12.60.

Alpha Tau Medical Company Profile

Alpha Tau Medical Ltd. is a medical technology company headquartered in Ness Ziona, Israel, focused on developing targeted alpha-radiation therapies for the treatment of solid tumors. The company’s core innovation, known as Diffusing Alpha-emitters Radiation Therapy (DaRT), employs short-lived radioactive isotopes to deliver high-energy alpha particles directly within or adjacent to tumor tissues. By harnessing the potent cytotoxic effects of alpha radiation, Alpha Tau Medical aims to offer a novel approach to brachytherapy that can potentially overcome radioresistance and spare surrounding healthy tissue.

The company’s lead product, Alpha DaRT, is currently being evaluated in clinical studies for a range of indications including recurrent or metastatic head and neck cancers, skin cancers, and other solid tumors.